Mtx Ratiopharm (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This inhibition reduces the production of purine and pyrimidine nucleotides, limiting the growth of rapidly dividing cells such as activated lymphocytes and cancer cells. An additional anti‑inflammatory effect is thought to arise from increased extracellular adenosine.

The dosage of methotrexate is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Dosing regimens can vary widely, ranging from low weekly doses for rheumatoid arthritis to higher, more intensive schedules for oncologic protocols. Patients should follow the exact dosing instructions provided by their healthcare professional.

Methotrexate is classified as teratogenic and is contraindicated in pregnancy because it can cause fetal malformations and miscarriage. Women of child‑bearing potential must use effective contraception during treatment and for a period after discontinuation. Breastfeeding is also discouraged, as methotrexate can be excreted in milk and may harm the infant.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifying trade or institutional credentials before providing a formal quotation. The team then confirms pricing, availability, shipping conditions (including cold‑chain if required) and assists with any necessary import documentation.

For autoimmune diseases, biologic disease‑modifying antirheumatic drugs (bDMARDs) such as TNF‑α inhibitors are common alternatives. Methotrexate is an oral or injectable conventional DMARD that is less expensive and has a long safety record, but it may be slower to achieve disease control. Biologics often provide faster symptom relief but carry higher costs and distinct infection risks. Choice depends on disease severity, patient preference and economic considerations.

Mtx Ratiopharm should be stored in a refrigerator at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If refrigeration is temporarily unavailable, the product may be kept at controlled room temperature for a limited period as specified in the product label, but it should be returned to refrigerated conditions as soon as possible.

Mtx Ratiopharm is supplied for subcutaneous injection. The dose is typically prepared by a qualified healthcare professional using a sterile syringe and injected into the subcutaneous tissue of the abdomen, thigh or upper arm. Patients should be instructed on proper injection technique, site rotation and disposal of sharps according to local regulations.

The most critical adverse events include bone marrow suppression leading to pancytopenia, severe hepatotoxicity that can progress to fibrosis or cirrhosis, and pulmonary toxicity such as interstitial pneumonitis. Additional serious concerns are renal impairment, severe cutaneous reactions (e.g., Stevens‑Johnson syndrome) and teratogenic effects. Prompt monitoring of blood counts, liver and kidney function is essential to mitigate these risks.

Methotrexate is contraindicated in patients who are pregnant, planning to become pregnant, or breastfeeding. It should also be avoided in individuals with severe hepatic disease, significant renal impairment, uncontrolled infections, or known hypersensitivity to methotrexate or its excipients. Patients with a history of alcohol abuse or existing bone marrow disorders require careful evaluation before initiating therapy.